Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: A case-control study

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 5, 2009, Pages 458-463

  Hosohata, Keiko ^a   Masuda, Satohiro ^a   Yonezawa, Atsushi ^a   Sugimoto, Mitsuhiro ^a   Takada, Yasutsugu ^b   Kaido, Toshimi ^b   Ogura, Yasuhiro ^b   Oike, Fumitaka ^b   Shinji, Uemoto ^b   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CYP2C19; CYP3A4; CYP3A5; Drug interaction; Proton pump inhibitor

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 3A5; RABEPRAZOLE; STEROID; TACROLIMUS;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG METABOLISM; EVENING DOSAGE; FEMALE; GENE EXPRESSION; GENOTYPE; HETEROZYGOTE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; LIVER GRAFT; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POSTOPERATIVE PERIOD;

EID: 71449116971     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.458     Document Type: Article

References (24)

1. Logan, A. J., Morris-Stiff, G. J., Bowrey, D. J. and Jurewicz, W. A.: Upper gastrointestinal complications after renal transplantation: a 3-yr sequential study. Clin. Transplant., 16: 163-167 (2002).
2. Shiraga, T., Matsuda, H., Nagase, K., Iwasaki, K., Noda, K., Yamazaki, H., Shimada, T. and Funae, Y.: Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol., 47: 727-735 (1994).
3. Hesselink, D. A., van Schaik, R. H., van der Heiden, I. P., van der Werf, M., Gregoor, P. J., Lindemans, J., Weimar, W. and van Gelder, T.: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther., 74: 245-254 (2003).
4. Kamdem, L. K., Streit, F., Zanger, U. M., Brockmoller, J., Oellerich, M., Armstrong, V. W. and Wojnowski, L.: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.Clin. Chem., 51: 1374-1381 (2005).
5. Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D. and Thummel, K. E.: Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab.Dispos., 34: 836-847 (2006).
6. Andersson, T.: Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet., 31: 9-28 (1996).
7. Homma, M., Itagaki, F., Yuzawa, K., Fukao, K. and Kohda, Y.: Effects of lansoprazole and rabeprazole on tacrolimus blood concentration: case of a renal transplant recipient with CYP2C19 gene mutation. Transplantation., 73: 303-304 (2002).
8. Takahashi, K., Motohashi, H., Yonezawa, A., Okuda, M., Ito, N., Yamamoto, S., Ogawa, O. and Inui, K.: Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism. Ann. Pharmacother., 38: 791-794 (2004).
9. Miura, M., Inoue, K., Kagaya, H., Satoh, S., Tada, H., Sagae, Y., Habuchi, T. and Suzuki, T.: Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm. Drug Dispos., 28: 167-175 (2007).
10. Hosohata, K., Masuda, S., Katsura, T., Takada, Y., Kaido, T., Ogura, Y., Oike, F., Egawa, H., Uemoto, S. and Inui, K.: Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab. Dispos., 37: 821-826 (2009).
11. Yasuda, S., Horai, Y., Tomono, Y., Nakai, H., Yamato, C., Manabe, K., Kobayashi, K., Chiba, K. and Ishizaki, T.: Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4?-hydroxylation status. Clin. Pharmacol. Ther., 58: 143-154 (1995).
12. Inomata, Y., Tanaka, K., Egawa, H., Uemoto, S., Ozaki, N., Okajima, H., Satomura, K., Kiuchi, T., Yamaoka, Y. and Hashida, T.: The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. Transplantation.,61: 247-252 (1996).
13. Yasuhara, M., Hashida, T., Toraguchi, M., Hashimoto, Y., Kimura, M., Inui, K., Hori, R., Inomata, Y., Tanaka, K. and Yamaoka, Y.: Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant. Proc., 27: 1108-1110 (1995).
14. Masuda, S., Uemoto, S., Goto, M., Fujimoto, Y., Tanaka, K. and Inui, K.: Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin. Pharmacol. Ther., 75: 352-361 (2004).
15. Kuypers, D. R., de Jonge, H., Naesens, M. and Vanrenterghem, Y.: Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics., 18: 861-868 (2008).
16. De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Meyer, U. A., Nakamura, K. and Goldstein, J. A.: Identification of a new genetic defect responsible for the polymorphism of (S)mephenytoin metabolism in Japanese. Mol. Pharmacol., 46: 594-598 (1994).
17. De Morais, S. M., Wilkinson, G. R., Blaisdell, J., Nakamura, K., Meyer, U. A. and Goldstein, J. A.: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J. Biol. Chem., 269: 15419-15422 (1994).
18. Goto, M., Masuda, S., Kiuchi, T., Ogura, Y., Oike, F., Okuda M., Tanaka, K. and Inui, K.: CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics., 14: 471-478 (2004).
19. Saeki, M., Saito, Y., Nakamura, T., Murayama, N., Kim, S. R., Ozawa, S., Komamura, K., Ueno, K., Kamakura, S., Nakajima, T., Saito, H., Kitamura, Y., Kamatani, N. and Sawada, J.: Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat., 21: 653 (2003).
20. Uesugi, M., Masuda, S., Katsura, T., Oike, F., Takada, Y. and Inui, K.: Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet. Genomics., 16: 119-127 (2006).
21. Fukudo, M., Yano, I., Yoshimura, A., Masuda, S., Uesugi, M., Hosohata, K., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Uemoto, S. and Inui, K.: Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet. Genomics., 18: 413-423 (2008).
22. Itagaki, F., Homma, M., Yuzawa, K., Nishimura, M., Naito, S., Ueda, N., Ohkohchi, N. and Kohda, Y.: Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations. J. Pharm. Pharmacol., 56: 1055-1059 (2004).
23. Fukudo, M., Yano, I., Masuda, S., Goto, M., Uesugi, M., Katsura, T., Ogura, Y., Oike, F., Takada, Y., Egawa, H., Uemoto, S. and Inui, K.: Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther., 80: 331-345 (2006).
24. Hosohata, K., Masuda, S., Ogura, Y., Oike, F., Takada, Y., Katsura, T., Uemoto, S. and Inui, K.: Interaction between tacrolimus and lansoprazole, but not rabeprazole in living-donor liver transplant patients with defects of CYP2C19 and CYP3A5. Drug Metab. Pharmacokinet., 23: 134-138 (2008).